Minerva Neurosciences, Inc. (NASDAQ: NERV) filed a shelf registration statement on March 11, 2026 that authorizes the company to offer up to $200 million in a mix of common stock, preferred stock, debt securities, and warrants. The filing does not yet specify the exact allocation among the different security types, but it provides the company with the flexibility to raise capital over time as needed.
The primary purpose of the offering is to fund the confirmatory Phase 3 trial of roluperidone, the company’s lead candidate for the treatment of negative symptoms of schizophrenia. The trial follows a Complete Response Letter from the FDA in February 2024 that required additional data before the drug could be approved. Securing this capital is therefore a critical step toward resubmitting a New Drug Application and potentially bringing the first FDA‑approved therapy for this unmet medical need.
Minerva’s financial position underscores the urgency of the raise. The company reported a net loss of $293.4 million for 2025 and an accumulated deficit of $688.8 million as of December 31, 2025. With no approved products generating revenue, the company relies on external financing to cover operating expenses and clinical development costs. The $200 million prospectus is intended to extend the company’s runway and support the substantial costs associated with a Phase 3 trial.
CEO Dr. Remy Luthringer emphasized the strategic alignment with the FDA and the importance of the new funding. “Strengthened by the recent financing and our general alignment with the U.S. Food and Drug Administration (“FDA”) on trial design, we are working towards initiation of the confirmatory Phase 3 trial with roluperidone for the treatment of negative symptoms of schizophrenia in the second quarter,” he said. He added, “With the $80 million upfront proceeds and the exercise proceeds from the Tranche A warrants, we anticipate sufficient funds to complete the Phase 3 trial and resubmission of the New Drug Application (“NDA”) ahead of the launch of roluperidone in the United States, if approved.” Luthringer also noted, “This does not happen very often, but here we have all the alignments necessary in order to move forward.”
The filing follows a highly positive investor response to a prior financing round announced in October 2025, when the company raised $80 million upfront and secured potential additional funds from warrant exercises. That round had a significant impact on investor sentiment, reflecting confidence that the company could secure the capital needed to advance its flagship program. The current prospectus continues that trajectory, providing a broader capital structure that can be deployed as the Phase 3 trial progresses.
While the capital raise is a positive development, the company still faces substantial headwinds. The Phase 3 trial carries inherent clinical and regulatory risks, and the company’s large accumulated deficit and ongoing cash burn remain a concern. Nevertheless, the potential approval of roluperidone would represent a first‑in‑class treatment for a largely unmet segment of schizophrenia, offering a significant tailwind that could transform the company’s commercial prospects if the trial succeeds.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.